9 posts in this category
California AB-1990 would raise ingredient, record-keeping, and advertising rules for compounded GLP-1 medications. What it could mean for you.
FDA statements, tariffs, and lawsuits have compounded GLP-1 patients' worries. Here is what is changing, what is not, and what it means for your price
FDA warned 30 telehealth companies over GLP-1 marketing claims. Learn what changed, why compounding is not going away, and what to look for.
Learn how GLP-1 insurance coverage works, including prior authorization, appeals, step therapy, and patient responsibilities.
How telehealth access to GLP-1s is changing in 2026, including intake, follow-up, transparency, and what members should expect.
Confused about how Medicare may cover GLP-1 weight loss drugs after the TrumpRx deal Learn who may qualify, expected costs, and key dates until 2027.
A clear look at the next wave of GLP-1 drugs in 2026 — launches, filings, access changes and what patients and payers should know.
From access issues to mindset and side effects, here are the most common mistakes people make on GLP-1 therapy—and how to fix them.
Trump’s plan could cut GLP-1 drug prices — like Ozempic® and Wegovy® — to $150/month. Here’s what’s real, what’s pending, and who it helps.
